Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
Pfizer’s stock falls despite fourth-quarter revenue and earnings beat. This analyst expects growth to accelerate.
Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...
The Motley Fool9d
Pfizer Beats Q4 Revenue, EPS Estimates
Revenue reached $17.8 billion ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Should You Pick PFE Stock At $25?
Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...
Pfizer: 3 Key Risks That Warrant A Sell
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Nasdaq9d
Pfizer Beats Q4 Revenue, EPS Estimates
Total revenue of $17.8 billion in the quarter ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management. Notably, Pfizer's R&D ...
Morningstar9d
Pfizer's stock falls despite fourth-quarter revenue and earnings beat. This analyst expects growth to accelerate.
Related: Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance "We expect sales of the COVID-19 vaccine to eventually stabilize, and these sales could provide cash flow for ...